Featured:
Jul 28 | Adaptimmune Sells Cell Therapy Assets to US WorldMeds read more »
Jul 28 | Genethon Receives Regulatory Approvals for Pivotal Phase 3 AAV Gene Therapy Trial for DMD in Europe read more »
Jul 28 | FDA Allows Sarepta to Resume Its Gene Therapy Shipments for Ambulatory Duchenne Patients read more »
News:
Jul 30 | Dx&Vx Inks Landmark $220M Global Out-Licensing Deal for mRNA Cancer Vaccine read more »
Jul 30 | Single AAV Gene Therapy Injection at Birth Shows Potential for Long-Term HIV Protection in Newborns read more »
Jul 30 | China Unveils Weight-Dependent Pricing for Hemophilia B Gene Therapy read more »
Jul 29 | uniQure Advances Gene Therapy AMT-130 for Huntington’s Disease read more »
Jul 28 | CHMP Recommends Moderna’s LP.8.1-Targeting COVID-19 mRNA Vaccine for 2025-2026 Season read more »
Jul 27 | Elpis Biopharmaceuticals and NCCS Partner on Next-Gen Cell Therapies for Solid Tumors read more »
Jul 25 | EMA Rejects Marketing Authorization for Sarepta’s DMD AAV Gene Therapy read more »
Articles:
Jul 30 | Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life read more »
Jul 30 | AGPAT4 targeted covalent inhibitor potentiates targeted therapy to overcome cancer cell plasticity in hepatocellular carcinoma mouse models read more »
Jul 30 | Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial read more »
Jul 29 | Treatment of GATA2 deficiency by allele-specific CRISPR/Cas9-directed gene correction in hematopoietic stem cells read more »
Jul 29 | Augmented germinal center and antibody responses to HIV Env trimers delivered as transmembrane immunogens by self-replicating RNA read more »
Jul 28 | Fetal rat neural progenitor cell transplantation after spinal cord injury improves motor recovery following optogenetic stimulation read more »
Jul 28 | Osteoarthritis gene therapy: Expanding the scope of genetic therapies read more »
Jul 28 | Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene read more »
Jul 26 | AAV9-mediated transduction of memory circuits following convection-enhanced delivery into the olfactory bulbs read more »
Jul 23 | Intrastriatal Delivery of a Zinc Finger Protein Targeting the Mutant HTT Gene Allele Obviates Lipid Phenotypes in Brain and Plasma in Huntington’s Disease Mice read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
